慢性乙型肝炎抗病毒治疗进展被引量：3

Progress in antiviral therapy for chronic hepatitis B

下载PDF

导出

摘要慢性乙型肝炎(chronic hepatitis B,CHB)的治疗目标是最大限度的长期抑制乙型肝炎病毒(hepatitis B virus,HBV)复制,减轻肝细胞炎性坏死及纤维化,但因为无法破坏共价闭合环状DNA(covalently closed circular DNA,cccDNA)和不适当的宿主免疫反应,很少能实现HBV的彻底清除。近年来,一些新型抗病毒剂的出现,为实现乙型肝炎治愈提供了可能。

作者罗雪曾爱中 LUO Xue;ZENG Ai-zhong

机构地区重庆医科大学附属第一医院感染科

出处《肝脏》 2019年第3期322-324,共3页 Chinese Hepatology

关键词慢性乙型肝炎抗病毒治疗共价闭合环状DNA 乙型肝炎病毒 CCCDNA 免疫反应抗病毒剂 HBV

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献2

1时红,李向永,朱建芸,林潮双,张英.恩替卡韦和替诺福韦酯治疗高病毒载量HBeAg阳性慢性乙型肝炎的对比分析[J].中华肝脏病杂志,2017,25(10):721-725. 被引量：31
2Wah Wah Phyo,Alex Yu Sen Soh,Seng Gee Lim,Guan Huei Lee.Search for a cure for chronic hepatitis B infection: How close are we?[J].World Journal of Hepatology,2015,7(9):1272-1281. 被引量：2

二级参考文献72

1World Health Organization. Hepatitis B. [Updated 2014 July].Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en.
2Uhl P, Fricker G, Haberkorn U, Mier W. Current status in thetherapy of liver diseases. Int J Mol Sci 2014; 15: 7500-7512 [PMID:24786290 DOI: 10.3390/ijms15057500].
3Grimm D, Thimme R, Blum HE. HBV life cycle and novel drugtargets. Hepatol Int 2011; 5: 644-653 [PMID: 21484123 DOI:10.1007/s12072-011-9261-3].
4Perrillo RP. Overview of treatment of hepatitis B: key approachesand clinical challenges. Semin Liver Dis 2004; 24 Suppl 1: 23-29[PMID: 15192798 DOI: 10.1055/s-2004-828675].
5Liaw YF. HBeAg seroconversion as an important end point inthe treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-433[PMID: 19669245 DOI: 10.1007/s12072-009-9140-3].
6Spangenberg HC, Thimme R, Blum HE. Tracking cccDNA inchronic HBV infection. Hepatology 2004; 39: 1736-1738 [PMID:15185317 DOI: 10.1002/hep.20272].
7Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extendedtreatment with peginterferon α-2a in combination with lamivudineor adefovir for 96 weeks yields high rates of HBeAg and HBsAgseroconversion. J Dig Dis 2013; 14: 446-450 [PMID: 23615131DOI: 10.1111/1751-2980.12065].
8Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J,Zhao M. Switching from entecavir to PegIFN alfa-2a in patientswith HBeAg-positive chronic hepatitis B: a randomised open-labeltrial (OSST trial). J Hepatol 2014; 61: 777-784 [PMID: 24915612DOI: 10.1016/j.jhep.2014.05.044].
9Seeger C, Mason WS. Hepatitis B virus biology. Microbiol MolBiol Rev 2000; 64: 51-68 [PMID: 10704474 DOI: 10.1128/MMBR.64.1.51-68.2000].
10Jilbert AR, Freiman JS, Gowans EJ, Holmes M, Cossart YE,Burrell CJ. Duck hepatitis B virus DNA in liver, spleen, andpancreas: analysis by in situ and Southern blot hybridization.Virology 1987; 158: 330-338 [PMID: 3590623 DOI: 10.1016/0042-6822(87)90205-4].